SecBot SecBot

American Made Pharmaceuticals Act of 2023

S. 3311 Sen. Tina Smith (D-MN) In committee
Bill text PDF
  1. Introduced Nov 15
  2. Committee Nov 15
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Nov 15, 2023Next: Senate vote
825d ago Jul 25, 2024: Committee on Banking, Housing, and Urban Affairs. Hearings held. Hearings printed: S.Hrg. 118-655.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 3 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

American Made Pharmaceuticals Act of 2023

Full summary2 paragraphs

This bill requires the Centers for Medicare & Medicaid Services to conduct a demonstration program that gives preference to domestically manufactured drugs under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

The program must be conducted in at least eight states and for at least seven years. Applicable drugs include critical drugs that are needed to respond to a public health emergency and that have a vulnerable global supply chain. Preference may take the form of reduced cost-sharing, preferential treatment on formularies, bonus payments, and other specified methods.

Library of Congress summary, Nov 15, 2023

Summary versions
  • Introduced in SenateNov 15, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.